Christopher Peetz Sells 7,489 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,489 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Mirum Pharmaceuticals Stock Down 0.1 %

Mirum Pharmaceuticals stock opened at $42.00 on Friday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a 50 day moving average price of $42.93 and a 200 day moving average price of $40.62. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $48.89. The company has a market capitalization of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the business earned ($0.57) EPS. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. grew its holdings in shares of Mirum Pharmaceuticals by 1.2% in the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after purchasing an additional 75,000 shares in the last quarter. State Street Corp grew its stake in shares of Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after acquiring an additional 29,017 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $28,913,000. Finally, Clearbridge Investments LLC grew its stake in Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock worth $23,931,000 after purchasing an additional 436,349 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on MIRM shares. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Citigroup raised their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.